A Pilot Placebo-Controlled Randomized Trial of Repeated High-Dose Intravenous Magnesium Sulphate and High-Dose Nebulized Budesonide for Severe Asthma in the Paediatric Emergency Department.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were young children, children and teenagers, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

Time to medical readiness for discharge was the primary outcome.

What Was Measured

PubMed files the paper under topics including Administration, Inhalation, Asthma, Bronchodilator Agents, Budesonide, Emergency Service, Hospital, Magnesium Sulfate and Nebulizers and Vaporizers.

Author keywords: asthma severity score, length of stay, magnesium intravenous therapy, serum magnesium level and steroid nebulized therapy.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Journal of paediatrics and child health), a journal based in Australia.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.